|Recombinant Human BACE1 protein (Catalog#10064-HCCH)|
|0.2 μm filtered solution in PBS|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human BACE1 extracellular domain (rhBACE1; Catalog#10064-HCCH; Met 1-Thr 457; NP_036236.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
Has cross-reactivity in ELISA with
Mouse BACE1 / ASP2
No cross-reactivity in ELISA with Human ADAM15 and Human cell lysate (293 cell line)
This antibody can be used at 1:1000-1:2000 with the appropriate secondary reagents to detect Human BACE1.
Beta-site APP-cleaving enzyme 1 (BACE1) is an aspartic-acid protease important in the formation of myelin sheaths in peripheral nerve cells. In the brain, This protein is expressed highly in the substantia nigra, locus coruleus and medulla oblongata. Strong BACE1 expression has also been described in pancreatic tissue. BACE1 has a pivotal role in the pathogenesis of Alzheimer's disease. In Alzheimer's disease patients, BACE1 levels were elevated although mRNA levels were not changed. It has been found that BACE1 gene expression is controlled by a TATA-less promoter. The translational repression as a new mechanism controlling its expression. And the low concentrations of Ca(2+) (microM range) significantly increased the proteolytic activity of BACE1. Furthermore, BACE1 protein is ubiquitinated, and the degradation of BACE1 proteins and amyloid precursor protein processing are regulated by the ubiquitin-proteasome pathway. It has also been identified as the rate limiting enzyme for amyloid-beta-peptide (Abeta) production.